These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
294 related items for PubMed ID: 11747337
1. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Wong NA, Brett L, Stewart M, Leitch A, Longley DB, Dunlop MG, Johnston PG, Lessells AM, Jodrell DI. Br J Cancer; 2001 Dec 14; 85(12):1937-43. PubMed ID: 11747337 [Abstract] [Full Text] [Related]
2. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A. Clin Cancer Res; 2000 Dec 14; 6(12):4797-802. PubMed ID: 11156237 [Abstract] [Full Text] [Related]
3. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. Cancer Res; 1995 Apr 01; 55(7):1407-12. PubMed ID: 7882343 [Abstract] [Full Text] [Related]
4. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG. Clin Cancer Res; 1998 May 01; 4(5):1243-50. PubMed ID: 9607583 [Abstract] [Full Text] [Related]
5. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. Ren DN, Kim IY, Koh SB, Chang SJ, Eom M, Yi SY, Seong SH, Kim MD, Bronner MP, Cho MY. J Surg Oncol; 2009 Dec 01; 100(7):546-52. PubMed ID: 19722231 [Abstract] [Full Text] [Related]
10. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Fernández-Contreras ME, Sánchez-Prudencio S, Sánchez-Hernández JJ, García de Paredes ML, Gisbert JP, Roda-Navarro P, Gamallo C. Int J Oncol; 2006 May 01; 28(5):1303-10. PubMed ID: 16596248 [Abstract] [Full Text] [Related]
11. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M, Nakao A. Anticancer Res; 2007 May 01; 27(2):851-6. PubMed ID: 17465211 [Abstract] [Full Text] [Related]
13. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B. Anticancer Res; 2010 Apr 01; 30(4):1149-56. PubMed ID: 20530421 [Abstract] [Full Text] [Related]
14. Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment. Trocha SD, Saha SS, Wiese D, Thompson J, Morton DL, Bilchik AJ. Am Surg; 2003 Oct 01; 69(10):918-22. PubMed ID: 14570375 [Abstract] [Full Text] [Related]
16. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Cancer Res; 2006 Oct 01; 66(19):9369-73. PubMed ID: 17018589 [Abstract] [Full Text] [Related]